We are live on ! Find out more
ProShare Advisors

ProShare Advisors Portfolio holdings

AUM $67.5B
1-Year Est. Return 28.09%
This Fund
S&P 500
This Quarter Est. Return
+9.54%
1 Year Est. Return
+28.09%
3 Year Est. Return
+88.43%
5 Year Est. Return
+118.21%
10 Year Est. Return
+464.8%
AUM
$21.6B
AUM Growth
+$3.73B
Cap. Flow
+$2.14B
Cap. Flow %
9.89%
Top 10 Hldgs %
20.71%
Holding
1,837
New
181
Increased
1,318
Reduced
286
Closed
50

Top Buys

Rank Stock Value
1
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$34M
2
XOM icon
ExxonMobil
XOM
+$33.1M
3
JNJ icon
Johnson & Johnson
JNJ
+$32.7M
4
MMM icon
3M
MMM
+$32.4M
5
MCD icon
McDonald's
MCD
+$32.3M

Sector Composition

Rank Sector Weight
1 Technology 20.41%
2 Financials 12.4%
3 Industrials 11.69%
4 Healthcare 11.57%
5 Consumer Staples 11.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ATHX
1776
DELISTED
Athersys, Inc. Common Stock
ATHX
$22K ﹤0.01%
726
+131
+22% +$4.29K
MDR
1777
DELISTED
McDermott International
MDR
$20K ﹤0.01%
29,709
+4,304
+17% +$5.5K
FET icon
1778
Forum Energy Technologies
FET
$605M
$19K ﹤0.01%
+561
New +$15.2K
NBEV
1779
DELISTED
NewAge, Inc. Common Stock (Delaware)
NBEV
$19K ﹤0.01%
+10,168
New +$24.1K
GEN
1780
DELISTED
Genesis Healthcare, Inc.
GEN
$19K ﹤0.01%
+11,354
New +$17K
CSLT
1781
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$18K ﹤0.01%
13,819
+2,208
+19% +$3.08K
XXII
1782
22nd Century Group
XXII
$1.45M
0
SENS icon
1783
Senseonics Holdings Inc
SENS
$266M
$15K ﹤0.01%
830
+132
+19% +$2.6K
LCTX icon
1784
Lineage Cell Therapeutics
LCTX
$274M
$13K ﹤0.01%
14,661
+2,343
+19% +$1.95K
FTR
1785
DELISTED
Frontier Communications Corp.
FTR
$13K ﹤0.01%
14,552
-473
-3% -$386
AXAS
1786
DELISTED
Abraxas Petroleum Corp
AXAS
$8K ﹤0.01%
1,086
+174
+19% +$1.12K
TEUM
1787
DELISTED
Pareteum Corporation
TEUM
$8K ﹤0.01%
17,455
+5,219
+43% +$3.01K
ABUS icon
1788
Arbutus Biopharma
ABUS
$875M
-15,394
Closed -$23K
ACET icon
1789
Adicet Bio
ACET
$74.4M
-103
Closed -$102K
ACRS icon
1790
Aclaris Therapeutics
ACRS
$786M
-14,710
Closed -$16K
ADAP
1791
DELISTED
Adaptimmune Therapeutics
ADAP
-22,483
Closed -$34K
ANAB icon
1792
AnaptysBio
ANAB
$1.6B
-10,120
Closed -$354K
ASRT
1793
DELISTED
Assertio
ASRT
-442
Closed -$34K
KALA icon
1794
KALA BIO
KALA
$13.9M
-5
Closed -$44K
LRMR icon
1795
Larimar Therapeutics
LRMR
$393M
-843
Closed -$7K
MNOV icon
1796
MediciNova
MNOV
$66M
-16,426
Closed -$131K
NERV icon
1797
Minerva Neurosciences
NERV
$200M
-1,742
Closed -$108K
OCUL icon
1798
Ocular Therapeutix
OCUL
$1.92B
-17,500
Closed -$53K
SVRA icon
1799
Savara
SVRA
$1.11B
-15,106
Closed -$40K
SYBX
1800
DELISTED
Synlogic
SYBX
-692
Closed -$24K

Similar funds

ProShare Advisors's Q4 2019 Portfolio in Review

As of Q4 2019, ProShare Advisors held 1,837 positions worth $21.6B, up 21% from $17.9B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

ProShare Advisors deployed $2.14B of net new capital in Q4 2019, opening 181 new positions and adding to 1,318 existing holdings. Its largest new stake was Pennant Group: 484,308 shares worth $16M.

By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was W.R. Berkley, an estimated $12.8M trimmed.

  • ProShare Advisors's largest Q4 2019 buy was Pennant Group: 484,308 shares worth $16M.
  • ProShare Advisors added most to Alphabet (Google) Class A in Q4 2019, an estimated $34M increase.
  • ProShare Advisors's biggest Q4 2019 reduction was W.R. Berkley, cutting an estimated $12.8M.
  • ProShare Advisors fully exited Celgene Corp in Q4 2019, selling an estimated $70M.
  • ProShare Advisors's ten largest holdings make up 21% of its $21.6B portfolio in Q4 2019.
  • ProShare Advisors opened 181 new positions and closed 50 in Q4 2019.
  • ProShare Advisors's portfolio value rose 21% quarter-over-quarter to $21.6B.

Based on ProShare Advisors's 13F filing for Q4 2019, filed 12 Feb 2020.